Feed PRMD.ME
Summary
56 / 100 · Bulios Score
Valuation 45Growth 43Profitability 66Quality 57Debt 57Stability 77
What speaks for it
- Out of every 100 RUB of revenue, 13 RUB is left as net profit.
- The price moves less than the market (beta 0.56).
What to watch
- Earnings per share fell by 22% a year over the last 3 years.
- It reports a profit, yet spends more cash than it brings in.
- You pay 29.7 RUB for 1 RUB of yearly profit, a lot for its sector.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedP/E against the industry (Drug Manufacturers - Specialty & Generic)
P/E today 29.7 Industry median 29.2
Today you pay 29.7 RUB for 1 RUB of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (RUB)
2021202220232024
Diluted EPS (RUB)
2021202220232024
Revenue grew by 9.4% a year over the last 3 years. Earnings per share fell by 22% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Cash and short-term investments 3.71B ₽
Debt 36.2B ₽
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail